Form S-4 | Jotup

Homology Medicines Declares Distribution to Common Stockholders

Retrieved on:

Monday, March 18, 2024

Failure, 600 (number), Growth, Form, Risk, COVID-19, Form S-4, XXV, Security (finance), Nature, XV, Annual report, File, CVR

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date.

Key Points:

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date.
The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024).
Certain statements contained in this filing may be considered forward-looking statements within the meaning of the U.S.
Homology can give no assurance that the conditions to the proposed transaction will be satisfied.

ESGEN Acquisition Corp. Announces Registration Statement Effectiveness in Connection with Business Combination with Sunergy Renewables

Retrieved on:

Tuesday, February 13, 2024

Acquisition, Proxy, Register, Special, Form, ESAC, Kirkland & Ellis, Business, Business analyst, Form S-4

DALLAS and NEW PORT RICHEY, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ESGEN Acquisition Corp. (“ESGEN”) (Nasdaq: ESACU, ESAC, ESACW), a publicly-traded special purpose acquisition company, and Sunergy Renewables, LLC (“Sunergy”), a leading Florida-based provider of residential solar and energy efficiency solutions, today announced that ESGEN’s registration statement on Form S-4, as amended (the “Registration Statement”) in connection with the previously announced proposed business combination (the “Business Combination”) with Sunergy has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”).

Key Points:

DALLAS and NEW PORT RICHEY, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ESGEN Acquisition Corp. (“ESGEN”) (Nasdaq: ESACU, ESAC, ESACW), a publicly-traded special purpose acquisition company, and Sunergy Renewables, LLC (“Sunergy”), a leading Florida-based provider of residential solar and energy efficiency solutions, today announced that ESGEN’s registration statement on Form S-4, as amended (the “Registration Statement”) in connection with the previously announced proposed business combination (the “Business Combination”) with Sunergy has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”).
The Registration Statement can be accessed on the SEC’s website at www.sec.gov .
ESGEN will mail the definitive proxy statement/prospectus (the “Proxy Statement”) to shareholders of record as of the close of business on February 7, 2024 (the “Record Date”).
The Proxy Statement contains a proxy card relating to the extraordinary general meeting of ESGEN’s shareholders (the “Special Meeting”).

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Retrieved on:

Wednesday, January 3, 2024

Failure, 600 (number), Risk, XV, Form, File, Common stock, Calendar, COVID-19, Nature, Form S-4, Letter, Growth, XXV, Indian stock exchange, Security (finance), Auction

BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“Nasdaq Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)).

Key Points:

Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement
BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“Nasdaq Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)).
The Nasdaq Notification has no immediate effect on the listing of the Common Shares on the Nasdaq Capital Market.
In accordance with the Nasdaq Notification, Homology has a compliance period of 180 calendar days from the date of the notification letter from Nasdaq, or until June 26, 2024, to regain compliance with the requisite minimum bid price requirement.
If, at any time before June 26, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten (10) consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement.

Quantum FinTech Acquisition Corporation Announces Effectiveness of Registration Statement and Special Meeting in Connection with its Proposed Business Combination with AtlasClear

Retrieved on:

Thursday, October 12, 2023

Professional Services, Finance, NYSE, Acquisition, Telephone, Special, Eastern Time Zone, Fintech, Internet, Quantum, Form, Form S-4, NYSE American, Registration statement, ALL, Register, Nelson Mullins Riley & Scarborough, Suite, Security (finance)

The Registration Statement provides important information about Quantum FinTech, AtlasClear and the business combination.

Key Points:

The Registration Statement provides important information about Quantum FinTech, AtlasClear and the business combination.
Quantum FinTech also announced it has established a record date of September 18, 2023 and a meeting date of November 3, 2023 for its special meeting of stockholders (the "Special Meeting") to approve the business combination with AtlasClear.
Accordingly, Quantum FinTech has also filed its definitive proxy statement relating to the Special Meeting with the SEC.
The closing of the business combination is subject to approval by Quantum FinTech's stockholders and the satisfaction of other customary closing conditions.

DLQ Announces Effectiveness of Registration Statement on Form S-4 in Connection with Pending Listing on NASDAQ via Merger with Abri SPAC I

Retrieved on:

Monday, October 2, 2023

SPAC, Form S-4, ABRI, DLQ, Special, ASPA, Register, Prospectus, Acquisition, OTCQX, Registration statement, Form, Proxy, Security (finance), Rock shelter

The registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission (SEC) by Abri on November 3, 2022, (as amended, the “Registration Statement”), was declared effective by the SEC on September 29.

Key Points:

The registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission (SEC) by Abri on November 3, 2022, (as amended, the “Registration Statement”), was declared effective by the SEC on September 29.
The Registration Statement was filed in connection with the previously announced merger of DLQ and Abri and contains a proxy statement and prospectus of Abri.
Logiq’s proxy statement contains important information about the proposed merger transactions, the merger agreement and the proposals to be considered at the Special Meeting.
Abri’s Registration Statement is available and may be accessed without charge on the SEC’s website at www.sec.gov (as filed under Abri SPAC I, Inc.).

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

Retrieved on:

Wednesday, September 6, 2023

Form S-4, Notability, Prospectus, VBL, Patient, Form, Therapy, Proxy, Airline, Pharmaceutical industry

MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”).

Key Points:

Merger with Notable expected to close in mid-October, subject to shareholder approval
Special shareholder meeting scheduled for October 12, 2023
MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”).
The definitive merger agreement between VBL and Notable was announced on February 23, 2023 and is expected to close in mid-October 2023, subject to customary closing conditions, including approval of the merger by VBL’s shareholders.
The registration statement contains a proxy statement / prospectus / information statement in connection with the merger.
“Having our registration statement on Form S-4 declared effective by the SEC is an important step towards the closing of our previously announced merger with Notable,” said Prof. Dror Harats, M.D., Chief Executive Officer of VBL.

KINS Technology Group Inc. Shareholders Approve Extension for Consummation of Business Combination to Acquire Workplace Experience Platform

Retrieved on:

Wednesday, December 14, 2022

The Extension provides KINS with additional time to complete the previously announced proposed business combination (the “Business Combination”) with CXApp Holding Corp. (“CXApp”).

Key Points:

The Extension provides KINS with additional time to complete the previously announced proposed business combination (the “Business Combination”) with CXApp Holding Corp. (“CXApp”).
On September 25, 2022, KINS entered into a definitive business combination agreement pursuant to which it would acquire CXApp and its workplace experience app platform and technologies, indoor mapping, events platform, augmented reality and related business solutions in exchange for 6.9 million shares of KINS capital stock valued at $69 million.
KINS Technology Group is focused on identifying and acquiring transformative technology businesses that are shaping the digital future and creating a new paradigm of communications and computing.
None of Inpixon, CXApp or KINS gives any assurance that Inpixon, CXApp or KINS will achieve their expectations.

Shift Closes Merger with CarLotz, Creating a Differentiated Used Omnichannel Auto Retailer, and Announces Shift Board of Directors Changes

Retrieved on:

Friday, December 9, 2022

Sumathi Best Television Current Reporting Award, William Blair & Company, Centerview Partners, SAN, Communication, LLP, Jenner & Block, Intelligence, Form S-4, SFT, Form, Video game, Security (finance), Shift

In connection with the closing, Jason Krikorian and Manish Patel resigned from the Shift Board of Directors, and Kimberly H. Sheehy, James E. Skinner, and Luis Ignacio Solorzano joined the Shift Board of Directors.

Key Points:

In connection with the closing, Jason Krikorian and Manish Patel resigned from the Shift Board of Directors, and Kimberly H. Sheehy, James E. Skinner, and Luis Ignacio Solorzano joined the Shift Board of Directors.
“On behalf of the Board and entire team at Shift, we’d like to thank Jason and Manish for their endless support, advice, and mentorship over the years,” said Jeff Clementz, Shift’s CEO.
Shift is a leading end-to-end auto ecommerce platform transforming the used car industry with a technology-driven, hassle-free customer experience.
The Company operates a technology-enabled buying, sourcing, and selling model that offers an omni-channel experience and diverse selection of vehicles.

Shift Closes Merger with CarLotz, Creating a Differentiated Used Omnichannel Auto Retailer, and Announces Shift Board of Directors Changes

Retrieved on:

Friday, December 9, 2022

In connection with the closing, Jason Krikorian and Manish Patel resigned from the Shift Board of Directors, and Kimberly H. Sheehy, James E. Skinner, and Luis Ignacio Solorzano joined the Shift Board of Directors.

Key Points:

In connection with the closing, Jason Krikorian and Manish Patel resigned from the Shift Board of Directors, and Kimberly H. Sheehy, James E. Skinner, and Luis Ignacio Solorzano joined the Shift Board of Directors.
“On behalf of the Board and entire team at Shift, we’d like to thank Jason and Manish for their endless support, advice, and mentorship over the years,” said Jeff Clementz, Shift’s CEO.
Shift is a leading end-to-end auto ecommerce platform transforming the used car industry with a technology-driven, hassle-free customer experience.
The Company operates a technology-enabled buying, sourcing, and selling model that offers an omni-channel experience and diverse selection of vehicles.

WaveTech Group, Inc., an Innovative Battery Technology Company, to List on Nasdaq Through Business Combination with Welsbach Technology Metals Acquisition Corp.

Retrieved on:

Tuesday, November 1, 2022

WaveTech Group, Inc. has entered into a definitive business combination agreement with Welsbach Technology Metals Acquisition Corp; upon closing, the combined company will be listed on Nasdaq under the proposed new ticker WTG.

Key Points:

WaveTech Group, Inc. has entered into a definitive business combination agreement with Welsbach Technology Metals Acquisition Corp; upon closing, the combined company will be listed on Nasdaq under the proposed new ticker WTG.
Net proceeds at closing will allow WaveTech to scale-up its Crystal Control Technology (CCT) for lead acid batteries and to commercialize CCTs application to other battery chemistries.
The Transaction positions WaveTech to accelerate the commercialization and further development of its disruptive battery technologies, building on its patented Crystal Control Technology.
WTMA believes the Transaction with WaveTech presents an opportunity to invest in a sector-disrupting and commercially-proven innovator in WTMAs target industry sectors of technology metals and energy transition materials.